SCHEMBL16664988

SCHEMBL16664988

CCCNc1cc(-c2ccnc(C)c2)ncn1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 10/20 0.44
MAP4K4 O95819 2/20 0.44
CDC7 O00311 1/20 0.44
ROCK2 O75116 1/20 0.44
PIM1 P11309 1/20 0.44
PRKACA P17612 1/20 0.44
CDK2 P24941 1/20 0.44
GSK3B P49841 1/20 0.44
HIPK2 Q9H2X6 1/20 0.44
MKNK2 Q9HBH9 1/20 0.44
IRAK4 Q9NWZ3 1/20 0.44
CYP1A2 P05177 13/20 0.43
CYP3A4 P08684 10/20 0.43
ALDH1A1 P00352 8/20 0.43
KDM4E B2RXH2 4/20 0.43
MEN1 O00255 3/20 0.43
KMT2A Q03164 3/20 0.43
MAPT P10636 3/20 0.43
CASP7 P55210 2/20 0.43
CYP2C19 P33261 7/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18627046 0.84 CYP1A2 (0.41) CLK4MAP4K4CDC7ROCK2PIM1
SCHEMBL16664967 0.82 CYP1A2 (0.45) CLK4MAP4K4CDC7ROCK2PIM1
SCHEMBL16664939 0.82 CLK4 (0.42) CLK4MAP4K4CDC7ROCK2PIM1
SCHEMBL18627048 0.81 ABL1 (0.44) CLK4MAP4K4CDC7ROCK2PIM1
SCHEMBL12907692 0.81 ABL1 (0.45) CLK4CYP1A2CYP3A4ALDH1A1MEN1
SCHEMBL18902711 0.79 CYP1A2 (0.53) CLK4CYP1A2CYP3A4ALDH1A1KDM4E
SCHEMBL22148218 0.79 MAP4K4 (0.47) CLK4MAP4K4CYP1A2CYP3A4ALDH1A1
SCHEMBL15343082 0.78 CYP1A2 (0.55) CLK4GSK3BCYP1A2CYP3A4ALDH1A1
SCHEMBL20415116 0.76 MAP4K4 (0.51) MAP4K4PIM1PIK3CAWNT3A
SCHEMBL15343155 0.75 CLK4 (0.40) CLK4MAP4K4CDC7ROCK2PIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015058031-A1 DNA-PK INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2015-04-23 WO disclosed